Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $3.18
Previous CloseN/A
Volume2.84M
Average Volume (3M)4.71M
Market Cap
$194.73M
Enterprise Value$174.15M
Total Cash (Recent Filing)$55.33M
Total Debt (Recent Filing)$30.82M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Apr 30, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding224,710,020
10 Day Avg. Volume6,407,115
30 Day Avg. Volume4,713,352
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.37
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$5.00Price Target Upside474.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Partnership OpportunitiesSGMO continues to advance discussions regarding a potential collaboration agreement around the study data.
Regulatory ApprovalThe positive eGFR slope for the first 23 patients is promising and could support potential accelerated approval.
Bears Say
Cash RiskPFE's decision increases cash overhang risk for SGMO, because the company will no longer be eligible for ~$70M milestone payment for BLA filing.
Program TerminationSGMO is down -49% after they announced partner PFE will not file BLA for hemA gene tx.
---
Ownership Overview
2.83% Insiders
12.95% Mutual Funds
7.24% Other Institutional Investors
69.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $194.73M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Apr 30, 2025 which is in 37 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Mar 17, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.019.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 224,710,020 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went down -15.842%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
---
Sangamo Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (474.71% Upside)
$5.00 (474.71% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 63.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.2%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.72%
12-Months-Change
Fundamentals
Return on Equity
-187.83%
Trailing 12-Months
Asset Growth
-36.30%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in Sangamo's neurology pipeline and strategic partnerships, along with financial achievements. However, challenges remain in securing a Fabry commercial partner and addressing financing needs, which are critical for future success.Read More>---
SGMO Stock 12 Month Forecast
Average Price Target
$5.00
▲(474.71% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+17.38%
reiterated a buy rating 7 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +17.38% per trade.
---